Streetbeat News

NVCT

Nuvectis Pharma, Inc.

https://www.nuvectis.com

Industry

Biotechnology

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Open

7.57

Mkt cap

181M

Volume

92K

High

7.89

P/E Ratio

-6.54

52-wk high

12.10

Low

7.42

Div yield

N/A

52-wk low

4.44

Nuvectis Pharma has successfully closed a $15.5 million public offering of common stock, including the full exercise of the underwriter's over-allotment option. The offering involved 2,700,000 shares at $5.00 each, plus an additional 405,000 shares.

Portfolio Pulse from

February 07, 2025 | 1:45 pm

Nuvectis Pharma, Inc. has announced the pricing of its public offering of 2.7 million shares at $5.00 each, aiming to raise $13.5 million. The underwriter has a 30-day option to purchase an additional 405,000 shares. The offering is expected to close on February 6, 2025.

Portfolio Pulse from

February 05, 2025 | 2:15 pm

Nuvectis Pharma, Inc. has announced a proposed public offering of its common stock, with an option for underwriters to purchase an additional 15%. The offering's completion is subject to market conditions.

Portfolio Pulse from

February 04, 2025 | 9:15 pm

Nuvectis Pharma (NVCT) has formed a hammer chart pattern, suggesting potential support and a possible trend reversal. This is supported by upward revisions in earnings estimates.

Portfolio Pulse from

November 25, 2024 | 4:15 pm

Nuvectis Pharma (NVCT) is highlighted as a strong option for trend investors due to its recent price trend and solid fundamentals. It has passed a short-term trading strategy screen, making it appealing for short-term investors.

Portfolio Pulse from

November 13, 2024 | 3:00 pm

Wall Street analysts predict a significant upside potential of 169.94% for Nuvectis Pharma (NVCT), driven by upward trends in earnings estimate revisions.

Portfolio Pulse from

November 07, 2024 | 4:15 pm

Nuvectis Pharma, Inc. (NASDAQ: NVCT) has released its third quarter 2024 financial results and business highlights, focusing on its progress in developing precision medicines for oncology.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

A new report highlights the potential of Nuvectis Pharma's NXP900 in non-small cell lung cancer (NSCLC) and anticipates upcoming data on NXP800. This positions Nuvectis among precision oncology leaders like Nuvalent and Summit Therapeutics.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 3:51 pm

Nuvectis Pharma, Inc. (NASDAQ:NVCT) will present its NXP900 at the 2024 AACR-NCI-EORTC Symposium, highlighting its focus on innovative cancer treatments.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:06 pm

In Wednesday's after-market session, several health care stocks experienced significant price movements. Molecular Templates (MTEM) saw a remarkable increase of 189.2%, while HCW Biologics (HCWB) experienced a notable decline of 14.8%. Other gainers included Klotho Neurosciences (KLTO) and Chromocell Therapeutics (CHRO), while Biodexa Pharmaceuticals (BDRX) and Capricor Therapeutics (CAPR) were among the losers.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.